Figure 6.

Illustration of IMD@Hf-DBP/αCD47 plus radiotherapy and PDT. (A) The design of RT-PDT induced ICD combined with the immunoadjuvant and ICB to systemically eradicate tumors. (B) Flow cytometry analysis of mature DCs. (C) Fluorescence intensity of MHC-II. *P < 0.05, and ***P < 0.005 from control. (D) Tumor growth curves with various treatments in CT26-bearing murine model. Black and red arrows refer to intratumoral injection and X-ray irradiation, respectively.

Note: Reprinted with permission from Ni K, Luo T, Culbert A, Kaufmann M, Jiang X, Lin W. Nanoscale Metal-Organic Framework Co-delivers TLR-7 Agonists and Anti-CD47 Antibodies to Modulate Macrophages and Orchestrate Cancer Immunotherapy. J Am Chem Soc. 2020;142(29):12579–12584. doi:10.1021/jacs.0c05039. Copyright 2020 American Chemical Society.¹¹⁷